Skip to main content
Top
Published in: Health Research Policy and Systems 1/2015

Open Access 01-12-2015 | Research

Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013

Authors: Srinivas Murthy, Kenneth D. Mandl, Florence T. Bourgeois

Published in: Health Research Policy and Systems | Issue 1/2015

Login to get access

Abstract

Background

Industry-sponsored clinical trials, in the past performed almost exclusively in more developed countries, now often recruit participants globally. However, recruitment from outside high-income countries may not represent the ultimate target population for the intervention. Clinical trial registries provide an opportunity to quantify and examine the type of clinical research performed in various geographic regions. We sought to characterize industry-sponsored randomized controlled trials conducted in high-income countries and to compare these trials to those performed outside high-income countries.

Methods

Clinical trial data on all industry-funded randomized controlled trials conducted between 2006 and 2014 were obtained from the registry ClinicalTrials.gov. Trials were classified according to their study sites as conducted in high or non-high income countries, and data on trial characteristics were collected.

Results

Of 22,511 relevant trials, a total of 6,085 (27.0 %) trials included study sites outside a high-income country, and 2,045 (9.1 %) were conducted exclusively outside high-income countries. Of country groups, Central Europe had the greatest number of trials (3,127), followed by Eastern Europe (2,075). The percentage of trials with study sites outside high-income countries remained relatively constant over the study period. Studies with sites outside high-income countries tended to recruit more participants (median enrolled participants 265 vs. 71, P <0.001), to be longer (median study duration 20 vs. 13 months, P <0.05), and to study more advanced phase interventions (Phase 3 or 4 trial 58 % vs. 33 %, P <0.001).

Conclusions

More than a quarter of industry-sponsored trials include participants from outside high-income countries and this rate remained stable over the 7-year study period. Trials conducted outside high-income countries tend to be larger, have a longer duration, and study later phase interventions compared to studies performed exclusively in high-income countries.
Appendix
Available only for authorised users
Literature
2.
go back to reference MacMahon S, Perkovic V, Patel A. Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA. 2013;310(9):907–8.CrossRefPubMed MacMahon S, Perkovic V, Patel A. Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA. 2013;310(9):907–8.CrossRefPubMed
3.
go back to reference Lorenzo C, Garrafa V, Solbakk JH, Vidal S. Hidden risks associated with clinical trials in developing countries. J Med Ethics. 2010;36(2):111–5.CrossRefPubMed Lorenzo C, Garrafa V, Solbakk JH, Vidal S. Hidden risks associated with clinical trials in developing countries. J Med Ethics. 2010;36(2):111–5.CrossRefPubMed
4.
go back to reference Khin NA, Yang P, Hung HM, Maung UK, Chen YF, Meeker-O’Connell A, et al. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Clin Pharmacol Ther. 2013;94(2):230–42.CrossRefPubMed Khin NA, Yang P, Hung HM, Maung UK, Chen YF, Meeker-O’Connell A, et al. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Clin Pharmacol Ther. 2013;94(2):230–42.CrossRefPubMed
5.
go back to reference Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816–23.CrossRefPubMed Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816–23.CrossRefPubMed
6.
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMed Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMed
7.
go back to reference Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308(16):1676–84.CrossRefPubMed Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308(16):1676–84.CrossRefPubMed
8.
go back to reference Siontis GC, Ioannidis JP. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol. 2011;40(5):1292–307.CrossRefPubMed Siontis GC, Ioannidis JP. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol. 2011;40(5):1292–307.CrossRefPubMed
10.
go back to reference Kaitin KI. The landscape for pharmaceutical innovation: drivers of cost-effective clinical research. Pharm Outsourcing. 2010;2010:3605.PubMedPubMedCentral Kaitin KI. The landscape for pharmaceutical innovation: drivers of cost-effective clinical research. Pharm Outsourcing. 2010;2010:3605.PubMedPubMedCentral
11.
go back to reference Imran M, Najmi AK, Rashid MF, Tabrez S, Shah MA. Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go. J Pharm Bioallied Sci. 2013;5(1):2–9.CrossRefPubMedPubMedCentral Imran M, Najmi AK, Rashid MF, Tabrez S, Shah MA. Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go. J Pharm Bioallied Sci. 2013;5(1):2–9.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ. 2013;346:f707.CrossRefPubMedPubMedCentral Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ. 2013;346:f707.CrossRefPubMedPubMedCentral
14.
go back to reference Zhang D, Freemantle N, Cheng KK. Are randomized trials conducted in China or India biased? A comparative empirical analysis. J Clin Epidemiol. 2011;64(1):90–5.CrossRefPubMed Zhang D, Freemantle N, Cheng KK. Are randomized trials conducted in China or India biased? A comparative empirical analysis. J Clin Epidemiol. 2011;64(1):90–5.CrossRefPubMed
15.
go back to reference Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials. 1998;19(2):159–66.CrossRefPubMed Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials. 1998;19(2):159–66.CrossRefPubMed
16.
go back to reference O’Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol. 2011;58(9):915–22.CrossRefPubMed O’Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol. 2011;58(9):915–22.CrossRefPubMed
17.
go back to reference Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet. 2003;4(12):937–47.CrossRefPubMed Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet. 2003;4(12):937–47.CrossRefPubMed
20.
21.
go back to reference Bernardez-Pereira S, Lopes RD, Carrion MJ, Santucci EV, Soares RM, de Oliveira AM, et al. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. Am Heart J. 2014;168(2):213–9.CrossRefPubMed Bernardez-Pereira S, Lopes RD, Carrion MJ, Santucci EV, Soares RM, de Oliveira AM, et al. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. Am Heart J. 2014;168(2):213–9.CrossRefPubMed
22.
go back to reference Bourgeois FT, Olson KL, Ioannidis JP, Mandl KD. Association between pediatric clinical trials and global burden of disease. Pediatrics. 2014;133(1):78–87.CrossRefPubMedPubMedCentral Bourgeois FT, Olson KL, Ioannidis JP, Mandl KD. Association between pediatric clinical trials and global burden of disease. Pediatrics. 2014;133(1):78–87.CrossRefPubMedPubMedCentral
24.
go back to reference Fiuzat M, Califf RM. Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. Heart Fail Clin. 2011;7(4):539–44.CrossRefPubMed Fiuzat M, Califf RM. Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. Heart Fail Clin. 2011;7(4):539–44.CrossRefPubMed
25.
go back to reference Shirotani M, Kurokawa T, Chiba K. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. J Clin Pharmacol. 2014;54(7):753–64.CrossRefPubMed Shirotani M, Kurokawa T, Chiba K. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. J Clin Pharmacol. 2014;54(7):753–64.CrossRefPubMed
26.
go back to reference Nair SC, Ibrahim H, Celentano DD. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur? Contemp Clin Trials. 2013;36(2):704–10.CrossRefPubMed Nair SC, Ibrahim H, Celentano DD. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur? Contemp Clin Trials. 2013;36(2):704–10.CrossRefPubMed
28.
go back to reference Petryna A. When experiments travel: clinical trials and the global search for human subjects: Princeton university press. Princeton, NJ: Princeton University Press; 2009.CrossRef Petryna A. When experiments travel: clinical trials and the global search for human subjects: Princeton university press. Princeton, NJ: Princeton University Press; 2009.CrossRef
Metadata
Title
Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013
Authors
Srinivas Murthy
Kenneth D. Mandl
Florence T. Bourgeois
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health Research Policy and Systems / Issue 1/2015
Electronic ISSN: 1478-4505
DOI
https://doi.org/10.1186/s12961-015-0019-6

Other articles of this Issue 1/2015

Health Research Policy and Systems 1/2015 Go to the issue